|
1
|
|
|
2
|
- Hospice of St. Tammany
- Palliative Care Institute of Southeast Louisiana
- Covington, LA
|
|
3
|
- 50 million people suffer from chronic pain
- Treatment with opioids is safe and effective
- New understanding of CNS changes in chronic pain provides rationale for
treatment
- Relief from suffering is our goal
|
|
4
|
- Assessing Pain
- Difference between Acute and Chronic
- Treatment of Pain
- Specific Opioids
- Adjuvants for Pain
- Side-effects
- Importance of Teamwork
|
|
5
|
- Detailed description of pain
- What makes it better or worse
- Effect on emotional, social status
- Do a physical assessment
- Review diagnostic and lab data
- Reassess often to adjust treatment
|
|
6
|
- Pathway for acute pain perception is conventional
- Duration is short
- Endorphins and enkephalins are released by CNS to block pain perception
- Opioids are effective for acute pain
|
|
7
|
- Prolonged pain impulses cause “burn-out” of the AMPA receptors involved
in pain transmission in the spinal cord
- Endorphins become less effective
- NMDA receptors, normally quiescient, are ACTIVATED, causing changes in
pain transmission and behavior
|
|
8
|
- Windup
- Neural remodeling
- Activation of NK-1 receptors
- Afferent becomes efferent
- Neurogenic inflammation
|
|
9
|
- Nociceptive(Somatic and Visceral) and Neuropathic Pain
- WHO 3-step analgesic ladder
- Step 1: Mild analgesics: APAP,
Propoxyphene, NSAIDS
- Step 2: Moderate analgesics:
Codeine, Hydrocodone/APAP,
Oxycodone/APAP, Tramadol
- Step 3: Strong Opioids
|
|
10
|
- Use WHO pain ladder to select analgesic
- Around-the-clock, q. 3-4 hr.
- Assess frequently, adjust dose
- Add up total opioid taken q. 24hr.
- Select long-acting opioid q. 12 hr.
- Use short-acting opioid for breakthrough pain prn.
- Use one short- and one long-acting
- Reassess to titrate dose
|
|
11
|
- Dilaudid(hydromorphone= 2mg
- Oxycodone = 5-10 mg
- Hydrocodone =15 mg
- Codeine = 60mg
- Ultram(tramadol) =50 mg
- Demerol(merperidine) =50 mg
- Fentanyl(duragesic)=see slide 16
- Levorphanol = 1-2 mg
|
|
12
|
|
|
13
|
- Morphine
- Oxycodone
- Dilaudid (Hydromorphone)
- Fentanyl
- Methadone
- Levorphanol
|
|
14
|
- Usual 1st. choice for moderate, severe pain. Begin low, 15mg
q 3-4 hr. Titrate ,reassess often.
- No ceiling
- Resp. depression rare in chronic pain patients.
- High doses: metabolites = nausea,dysphoria, muscle jerks
|
|
15
|
- Beginning dose 2-4 mg q 3-4 hr. Very effective, similar to MS.
- Less nausea. No ceiling. Often
used orally for breakthrough pain and i.v.
- No sustained-release form.
- 2 mg = 10 mg MS
|
|
16
|
- Starting oral dose 5-10 mg q 3-4 hr. Very effective
- Less nausea, less troublesome metabolites.Combined with ASA and APAP
(Percocet,etc.), limits ceiling.
- Expensive sustained-release form (Oxycontin), no ceiling. Watch for
illegal diversion. Oxycontin 10,20,40,80mg.
- Liquid concentrate 20mg/ml useful
buccally in the dying, as is MS(Roxanol).
|
|
17
|
- Duragesic patch: use care in opioid- naïve patient-use 25 mcg/hr first,
after pain controlled by short-acting opioid.
- To calculate dose, convert any
and all opioids to their morphine-equivalent/24 hr first.
- 12 hr delay in onset and offset due to skin reservoir absorption.
|
|
18
|
- Fever increases absorption rate. Avoid skin with scant subcut. fat.
- 25mcg patch= 50 mg MS /24 hrs
- 50 ‘ ‘ = 100 mg “
- 75 “ “ = 150 mg “
- 100 “ “
= 200mg “
- (approx.)
|
|
19
|
- Under-used, not marketed
- NMDA receptor-blocking activity makes these, especially methadone, the
best choice for neuropathic and complex chronic pain
- Levorphanol is 4-8x stronger than MS: longer ½ life (q 6 hrs)
|
|
20
|
- Long duration of action
- Short initial distribution half-life
- No active metabolites
- No ceiling dose
- NMDA receptor-blocker action in spinal cord (important in neuropathic
and chronic pain)
- Cost: approx. $20-25/month( vs. $200-500/mo. for hydromorphone,sust.act.
morphine,oxycodone,fentanyl patch.
|
|
21
|
- Potency at least equal to
morphine
- Oral, rectal absorption excellent
- Low incidence of side-effects
- Less constipating
- Lower incidence of tolerance
- Available for iv infusion use
- Most important,methadone is both a mu opioid agonist and an NMDA
receptor antagonist as it relates to pain relief
|
|
22
|
- Stigma and association with substance-abuse
- Accumulation due to long and variable elimination half-life in some
persons
- Said to be hard to convert to and from other opioids
- Fear of regulators
- Lack of education and experience
|
|
23
|
- Duragesic Patch 25mcg/hr $ 140
- Duragesic Patch 100 mcg/hr $ 430
- Oxycontin 40 mg q 12 hr $
250
- MS contin 60 mg q 12 hr $
210
- Dilaudid 4 mg q 4 hr ATC $
118
- Percocet 5 mg q 4 hr ATC $ 210
- Levorphanol 2 mg q 6 hr $
120
- Methadone 10 mg q 8 hr
$ 20
|
|
24
|
|
|
25
|
|
|
26
|
- Palliative Care Consults(total) 140:
- Methadone for Chronic pain: 88
- Excellent relief( pain
reduced from 7-10 to 0-3) : 50
- Fair relief (pain reduced to
4-6): 18
- No benefit or side-effects:
20
- ( Nausea 6, Sedation 12,
Depression 2)
|
|
27
|
- For Neuropathic pain:
- Tricyclic antidepressants
- Anticonvulsants
- For bone and soft-tissue pain:
-
NSAIDs,corticosteroids,palliative radiation,biphosphonates,
tricyclics
- For visceral pain:
corticosteroids,H-2 blockers,metoclopropamide
|
|
28
|
|
|
29
|
|
|
30
|
- Good sleep
- Pain free at rest
- Pain free during activities
|
|
31
|
- Nociceptive pain
- Neuropathic pain
|
|
32
|
- 65% nociceptive
- 5% neuropathic
- 30% mixed
|
|
33
|
- Tertiary amine
- Amytriptaline (Elavil)
- Impramine (Tofranil)
- Secondary amine
- Nortriptyline (Pamelor)
- Desipramine (Norprimine)
- Secondary amines have equal 5HT, NE potency
- Secondary amines have half the side effects
|
|
34
|
- One adjuvant at a time, targeted to the specific symptom
- Tricyclic antidepressants (amitriptyline, nortriptyline, desipramine,
venlafaxine) for pain described as “constant burning pain”
- Anticonvulsants (Gabapentin, valproate, carbamazepine, clonazepam) for
pain described as “shooting, stabbing, electric shock pain”
|
|
35
|
- Inhibit excessive neuronal activity
- Inhibit excitatory systen
- Activate inhibitory
|
|
36
|
- N = 22 cancer patients with refractory pain
- Gabapentin was added to opioid treatment
- Results
- Pain decreased from 6.4 to 2.1 (0 - 10 scale)
- Burning pain decreased from 5.1 to 2.0
- Shooting pain decreased from 7.2 to 2.2
- Allodynia disappeared in 7 0f 9
- Caraceni et al j Pain Sympt Manag 1999; 17:441-445
|
|
37
|
- N = 28, double-blind, cross-over
- Gabapentin 900-1800 mg/day
- Amitriptyline 25-75 mg/day
- Results: No difference in pain relief or global pain score data
- Moderate or greater pain relief in 52% of GBP vs. 67% (AMT)
- Arch Intern Med 1999;159:1931-1937
|
|
38
|
- TCA – 10 - 100 mg
- AED – full dose, except Valproic acid(usually 250 mg once daily hs.)
|
|
39
|
- Opioid adverse effects: nausea,constipation,somnolence, dysphoria, muscle jerks, itching, respiratory depression
- Neuropathic adjuvant side-effects: dizziness ,sleepiness, low BP, liver
toxicity(uncommon)
- NSAID side-effects: nausea, GI ulcer or bleeding, edema,decreased renal
function
|
|
40
|
- Complex chronic pain, especially if caused by life-threatening disease,
is best treated by a team.
- The diverse talents of physician, nurse, social worker, chaplain,
working together offers comprehensive control of physical, emotional,
and spiritual pain.
- Palliative care is for ALL patients who are suffering.
|